Sensus Healthcare (SRTS) Expected to Announce Earnings on Thursday

Key Points

• Sensus Healthcare (NASDAQ:SRTS) is set to announce its Q2 2025 earnings on August 7th, with expectations of $0.01 earnings per share and revenue of $9.30 million.
• The company reported a loss of ($0.16) EPS in its previous quarter, missing estimates by $0.20, but exceeded revenue expectations with $8.34 million against a $7.23 million estimate.
• Analysts have mixed views on the stock, with recent reports downgrading its rating to "sell," while others maintain "buy" ratings but adjust target prices downwards.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect Sensus Healthcare to post earnings of $0.01 per share and revenue of $9.30 million for the quarter.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.20). The firm had revenue of $8.34 million for the quarter, compared to analysts' expectations of $7.23 million. Sensus Healthcare had a return on equity of 3.34% and a net margin of 4.56%. On average, analysts expect Sensus Healthcare to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sensus Healthcare Stock Performance

Sensus Healthcare stock traded down $0.04 during trading hours on Monday, reaching $5.54. 164,858 shares of the stock were exchanged, compared to its average volume of 183,154. The stock has a market cap of $91.11 million, a P/E ratio of 55.40 and a beta of 1.34. Sensus Healthcare has a 52-week low of $4.01 and a 52-week high of $9.33. The firm's 50 day moving average is $4.82 and its 200 day moving average is $5.05.

Analyst Ratings Changes

SRTS has been the topic of several analyst reports. Maxim Group decreased their price target on shares of Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Wall Street Zen cut shares of Sensus Healthcare from a "hold" rating to a "sell" rating in a research report on Sunday, June 22nd.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.